title: FTIR spectral study of intramolecular hydrogen bonding in thromboxane A2 receptor antagonist S-145 and related compounds. 3. Conformation and activity of S-145 analogues.
abstract: S-145, (+/-)-(5Z)-7-[3-endo-[(phenylsulfonyl)amino]bicyclo[2.2.1] heptenoic acid, its chain analogues HO2C(CH2)nNHSO2Ph (n = 3-8, 10, and 11) 1-8, and (5Z)-9-(phenylsulfonyl) aminonon-5-enoic acid (9) were synthesized in order to elucidate the dependence of the conformation in solution and of the pharmacological activity on the side-chain length. Their FTIR spectra were measured in dilute CCl4 solution. For these compounds, intramolecular hydrogen bonds similar to those observed for S-145 were found between the carboxyl and sulfonamido groups. A linear relationship was also found between the percentage (rho) of the intramolecular hydrogen-bonded molecules and the n value. Compounds 1-9 were examined in vitro for inhibitory concentrations (IC50) against U-46619- and collagen-induced aggregations for rabbit and rat washed platelets (WP), respectively, and U-46619-induced contraction for rat aorta. Three kinds of TXA2 receptor antagonistic potencies [log(1/IC50)] showed parabolic correlations with the n value, though the rho value was in direct proportion to the n value. The log (1/IC50) values for 6 (n = 8), which forms a 12-membered ring similar to the one observed for S-145, were found to be maximal values in 1-8 and were comparable to those for BM-13177. In compounds 9 (rho = 83%) and S-145 (rho = 89%), the IC50 values of 41 and 2.9 nM for rat WP were 10 and 141 times lower than that of 6 (rho = 52%), respectively. In these compounds, which form the 12-membered ring, the inhibitory potencies increase as the rho value increases.
authors.affiliation: Shionogi Research Laboratories, Shionogi & Company, Ltd., Osaka, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Takasuka
authors.forename: M
authors.initials: M
authors.lastname: Yamakawa
authors.forename: M
authors.initials: M
authors.lastname: Ohtani
mesh_terms: D000818:Animals; D001643:Bridged Bicyclo Compounds / Q000494:pharmacology*; D005229:Fatty Acids, Monounsaturated / Q000494:pharmacology*; D005583:Fourier Analysis; D006859:Hydrogen / Q000737:chemistry*; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D011817:Rabbits; D051381:Rats; D011982:Receptors, Prostaglandin / Q000037:antagonists & inhibitors*; D017482:Receptors, Thromboxane; D013055:Spectrophotometry, Infrared; D013329:Structure-Activity Relationship; D013931:Thromboxanes / Q000378:metabolism*
chemical_list: D001643:Bridged Bicyclo Compounds; D005229:Fatty Acids, Monounsaturated; D010975:Platelet Aggregation Inhibitors; D011982:Receptors, Prostaglandin; D017482:Receptors, Thromboxane; D013931:Thromboxanes; C056566:S 145; D006859:Hydrogen